ELVN Q2 2021 Earnings — Enliven Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ELVNEnliven Therapeutics, Inc.

$2B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$25,000

Operating Income

-$13M

Net Income

-$13M

EPS (Diluted)

$-2.97

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$10M

Free Cash Flow

-$10M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$72M

Total Liabilities

$8M

Stockholders' Equity

$65M

Cash & Equivalents

$48M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$25,000	$0	—
Operating Income	-$13M	-$10M	-27.8%
Net Income	-$13M	-$10M	-29.0%